Covered recipient · General Payments record
VINCENT T HO
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2019–2025
$93,070.94
- Reported across 80 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,360.00 | 3 |
| Food and Beverage | $128.18 | 5 |
| Education | $43.25 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $9,360.00 | 3 |
| Novo Nordisk AS | $54.27 | 3 |
| JAZZ PHARMACEUTICALS INC. | $48.21 | 1 |
| Acerta Pharma LLC | $43.25 | 1 |
| Otsuka America Pharmaceutical, Inc. | $25.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $2,340.00 | 04/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202919864 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,510.00 | 06/26/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202955838 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,510.00 | 12/01/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202970260 | CMS |
| AstraZeneca Pharmaceuticals LP | $43.25 | 11/25/2025 | Education | Undisputed | 06/30/2026 | 1207143340 | CMS |
| JAZZ PHARMACEUTICALS INC. | $48.21 | 02/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234313521 | CMS |
| Novo Nordisk Inc | $21.47 | 06/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189075076 | CMS |
| Novo Nordisk Inc | $15.46 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189160252 | CMS |
| Novo Nordisk Inc | $17.34 | 08/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188588327 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.70 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227350389 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.